Ukrainian government may fix prices for imported drugs

5 October 2013

The government of Ukraine is considering fixing the prices of the drugs sold in the country, according to Ukraine’s Deputy Prime Minister Konstantin Grishchenko.

The Ukrainian pharmaceutical market grew by 17% in 2012 and reached a value of 30 billion hryvnia ($3.75 billion). This year, growth of the market is expected to slow down to 11%.

According to state plans, this is expected to take place through the introduction of a scheme of reference pricing, which will ensure that prices for drugs in Ukraine will be comparable with those for the same drugs in foreign countries, and in particular the European Union and USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >